BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 29530846)

  • 1. Micafungin Breakthrough Fungemia in Patients with Hematological Disorders.
    Kimura M; Araoka H; Yamamoto H; Nakamura S; Nagi M; Yamagoe S; Miyazaki Y; Ogura S; Mitsuki T; Yuasa M; Kaji D; Kageyama K; Nishida A; Taya Y; Shimazu H; Ishiwata K; Takagi S; Yamamoto G; Asano-Mori Y; Uchida N; Wake A; Taniguchi S; Yoneyama A
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Associated with Breakthrough Fungemia Caused by
    Kimura M; Asano-Mori Y; Sakoh T; Abe M; Ueno K; Hoshino Y; Nakamura S; Umeyama T; Yamagoe S; Miyazaki Y; Baba M; Okada C; Ogura S; Mitsuki T; Yamaguchi K; Yuasa M; Kaji D; Kageyama K; Nishida A; Taya Y; Ishiwata K; Takagi S; Yamamoto H; Yamamoto G; Uchida N; Wake A; Taniguchi S; Araoka H
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0208121. PubMed ID: 35041512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breakthrough Trichosporon asahii fungemia in neutropenic patient with acute leukemia while receiving caspofungin.
    Bayramoglu G; Sonmez M; Tosun I; Aydin K; Aydin F
    Infection; 2008 Feb; 36(1):68-70. PubMed ID: 17882360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Microbiological Characteristics of Breakthrough Candidemia in Allogeneic Hematopoietic Stem Cell Transplant Recipients in a Japanese Hospital.
    Kimura M; Araoka H; Yamamoto H; Asano-Mori Y; Nakamura S; Yamagoe S; Ohno H; Miyazaki Y; Abe M; Yuasa M; Kaji D; Kageyama K; Nishida A; Ishiwata K; Takagi S; Yamamoto G; Uchida N; Izutsu K; Wake A; Taniguchi S; Yoneyama A
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of animal infection models and antifungal efficacy assays against clinical isolates of Trichosporon asahii, T. asteroides and T. inkin.
    Mariné M; Bom VL; de Castro PA; Winkelstroter LK; Ramalho LN; Brown NA; Goldman GH
    Virulence; 2015; 6(5):476-86. PubMed ID: 25751127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The epidemiology, genotypes, antifungal susceptibility of Trichosporon species, and the impact of voriconazole on Trichosporon fungemia patients.
    Kuo SH; Lu PL; Chen YC; Ho MW; Lee CH; Chou CH; Lin SY
    J Formos Med Assoc; 2021 Sep; 120(9):1686-1694. PubMed ID: 33358563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and antifungal susceptibility study on trichosporonemia and emergence of Trichosporon mycotoxinivorans as a bloodstream pathogen.
    Dabas Y; Xess I; Kale P
    Med Mycol; 2017 Jul; 55(5):518-527. PubMed ID: 27816903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin.
    Matsue K; Uryu H; Koseki M; Asada N; Takeuchi M
    Clin Infect Dis; 2006 Mar; 42(6):753-7. PubMed ID: 16477548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal Disseminated Infection by Trichosporon asahii Under Voriconazole Therapy in a Patient with Acute Myeloid Leukemia: A Review of Breakthrough Infections by Trichosporon spp.
    Ramírez I; Moncada D
    Mycopathologia; 2020 Apr; 185(2):377-388. PubMed ID: 31853871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Treatment of Breakthrough Trichosporon asahii Fungemia by the Combination Therapy of Fluconazole and Liposomal Amphotericin B in a Patient with Follicular Lymphoma.
    Itoh K; Iwasaki H; Negoro E; Shigemi H; Tokimatsu I; Tsutani H; Yamauchi T
    Mycopathologia; 2021 Mar; 186(1):113-117. PubMed ID: 33389484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia.
    Asada N; Uryu H; Koseki M; Takeuchi M; Komatsu M; Matsue K
    Clin Infect Dis; 2006 Aug; 43(4):e39-41. PubMed ID: 16838224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of bloodstream co-infection of Saccharomyces cerevisiae and Candida glabrata while using micafungin.
    Furuya K; Ito K; Sugiyama K; Tokuda S; Kanemoto H; Kamei K; Shimada T
    BMC Infect Dis; 2023 May; 23(1):329. PubMed ID: 37193982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MALDI-TOF MS characterisation, genetic diversity and antifungal susceptibility of Trichosporon species from Iranian clinical samples.
    Ahangarkani F; Ilkit M; Vaseghi N; Zahedi N; Zomorodian K; Khodavaisy S; Afsarian MH; Abbasi K; de Groot T; Meis JF; Badali H
    Mycoses; 2021 Aug; 64(8):918-925. PubMed ID: 33998718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Echinocandin resistance among Candida isolates at an academic medical centre 2005-15: analysis of trends and outcomes.
    McCarty TP; Lockhart SR; Moser SA; Whiddon J; Zurko J; Pham CD; Pappas PG
    J Antimicrob Chemother; 2018 Jun; 73(6):1677-1680. PubMed ID: 29506044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.
    Pfaller MA; Castanheira M; Messer SA; Jones RN
    Mycoses; 2015 Apr; 58(4):209-14. PubMed ID: 25727853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breakthrough fungemia due to Candida fermentati with fks1p mutation under micafungin treatment in a cord blood transplant recipient.
    Konuma T; Takahashi S; Kiyuna T; Miharu Y; Suzuki M; Shibata H; Kato S; Takahashi S; Tojo A
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27859978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal susceptibility trend and analysis of resistance mechanism for Candida species isolated from bloodstream at a Japanese university hospital.
    Sakagami T; Kawano T; Yamashita K; Yamada E; Fujino N; Kaeriyama M; Fukuda Y; Nomura N; Mitsuyama J; Suematsu H; Watanabe H; Asai N; Koizumi Y; Yamagishi Y; Mikamo H
    J Infect Chemother; 2019 Jan; 25(1):34-40. PubMed ID: 30401513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular identification and susceptibility testing of Trichosporon isolates from a Brazilian hospital.
    Araujo Ribeiro M; Alastruey-Izquierdo A; Gomez-Lopez A; Rodriguez-Tudela JL; Cuenca-Estrella M
    Rev Iberoam Micol; 2008 Dec; 25(4):221-5. PubMed ID: 19071890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea.
    Jung SI; Shin JH; Song JH; Peck KR; Lee K; Kim MN; Chang HH; Moon CS;
    Med Mycol; 2010 Jun; 48(4):669-74. PubMed ID: 20392145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.